Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now discovered a molecular-level

A Yale study finds the protein #METTL7A triggers early resistance to #osimertinib by reshaping DNA architecture. Targeting METTL7A could help block resistance before it starts. #lungcancer #adenocarcinoma
➡️ yalecancercenter.org/news-article...